LPX Lipoxen

 

TIDMLPX 
 
RNS Number : 2637C 
Lipoxen PLC 
10 November 2009 
 

Lipoxen PLC 
("Lipoxen" or "the Company") 
 
 
Additional listing 
 
 
London, UK, 10 November 2009 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical 
company specialising in the development of high value differentiated 
biologicals, vaccines and siRNA delivery, announces that application has been 
made to AIM, a market of the London Stock Exchange plc, for the admission of 
187,145 ordinary shares of 0.5p each (the "New Ordinary Shares"). 
 
 
The New Ordinary Shares are being admitted pursuant to the exercise of options 
under the Lipoxen Plc Unapproved Share Option Plan. 
 
 
It is expected that dealings in the New Ordinary Shares, which will rank pari 
passu in all respects with the existing issued share capital of the Company, 
will commence on 11 November 2009. 
 
 
Enquiries 
 
+-------------------------------------------------+-------------------------+ 
| Lipoxen plc                                     |    +44 (0)20 7691 3583  | 
+-------------------------------------------------+-------------------------+ 
| M. Scott Maguire, Chief Executive Officer       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Singer Capital Markets (nominated adviser)      |     +44 (0)20 3205 7500 | 
+-------------------------------------------------+-------------------------+ 
| Jeff Keating / Claes Spång                      |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Noble & Company                                 |   +44 (0) 20 7763 2200  | 
+-------------------------------------------------+-------------------------+ 
| John Llewellyn-Lloyd / Sam Reynolds             |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Buchanan Communications                         |     +44 (0)20 7466 5000 | 
+-------------------------------------------------+-------------------------+ 
| Lisa Baderoon, Rebecca Skye Dietrich, Catherine |                         | 
| Breen                                           |                         | 
+-------------------------------------------------+-------------------------+ 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 LISEANFEFSLNFEE 
 

Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025

Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025